152 related articles for article (PubMed ID: 37893574)
1. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
[No Abstract] [Full Text] [Related]
2. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab simultaneous combined with dexamethasone implant for treatment of neovascular serous retinal pigment epithelial detachment secondary to neovascular age-related macular degeneration.
Limon U; Sezgin Akcay BI
Eur J Ophthalmol; 2022 Sep; 32(5):NP32-NP36. PubMed ID: 33781113
[TBL] [Abstract][Full Text] [Related]
6. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
[TBL] [Abstract][Full Text] [Related]
7. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
[TBL] [Abstract][Full Text] [Related]
9. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
[TBL] [Abstract][Full Text] [Related]
11. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
12. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
13. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
[TBL] [Abstract][Full Text] [Related]
14. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
[TBL] [Abstract][Full Text] [Related]
15. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
16. Scleritis following intravitreal brolucizumab injection: a case series.
Takayama T; Inoda S; Takahashi H; Tsukii R; Yoshida H; Kasuya Y; Nagaoka K; Takahashi R; Arai Y; Kawashima H
J Med Case Rep; 2024 Feb; 18(1):80. PubMed ID: 38419100
[TBL] [Abstract][Full Text] [Related]
17. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
18. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of brolucizumab in nAMD.
Narnaware SH; Bansal A; Bawankule PK; Raje D
Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S27-S32. PubMed ID: 38131538
[TBL] [Abstract][Full Text] [Related]
20. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]